USPTO Examiner CHESTNUT BARRY A - Art Unit 1672

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19182727VACCINATION OF IMMUNOCOMPROMISED SUBJECTSApril 2025October 2025Allow610YesNo
19182766VACCINATION OF IMMUNOCOMPROMISED SUBJECTSApril 2025September 2025Allow510YesNo
19075180COMPOSITIONS AND METHODSMarch 2025August 2025Allow510NoNo
19031360HERPES ZOSTER mRNA VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOFJanuary 2025August 2025Allow700NoNo
18938932GALLID ALPHAHERPESVIRUS 3 (MDV-2), A VIRAL VECTOR AGAINST DIFFERENT AVIAN PATHOGENS: A NEW VACCINATION STRATEGY IN THE POULTRY INDUSTRYNovember 2024April 2025Allow500NoNo
18630996ENGINEERING AAVApril 2024May 2025Allow1310NoNo
18611550MODIFIED VIRAL PARTICLES FOR GENE THERAPYMarch 2024June 2025Allow1510NoNo
18234573VARIANT CLASSIFICATION THROUGH HIGH-CONFIDENCE MUTATION DETECTION FROM FLUORESCENCE SIGNALS MEASURED WITH A MULTIPLE MUTATION ASSAYAugust 2023January 2026Allow2900NoNo
18350263Devices and Methods for Detecting Microorganisms Using Recombinant Reproduction-Deficient Indicator BacteriophageJuly 2023August 2025Allow2510NoNo
18036631INFLUENZA VIRUS ENCODING A TRUNCATED NS1 PROTEIN AND A SARS-COV RECEPTOR BINDING DOMAINMay 2023March 2026Allow3410NoNo
18130166ACTIVATION OF RESIDENT MEMORY T CELLS FOR CANCER IMMUNOTHERAPYApril 2023August 2025Allow2920NoNo
18029576CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS M-SEGMENT NUCLEIC ACID VACCINE AND METHODS OF USE AND PRODUCTIONMarch 2023November 2025Allow3100NoNo
18028613IMPROVED DNA VACCINE FOR SARS-COV-2March 2023March 2026Allow3510NoNo
18042913NOVEL CORONAVIRUS RECOMBINANT SPIKE PROTEIN, POLYNUCLEOTIDE ENCODING SAME, VECTOR COMPRISING POLYNUCLEOTIDE, AND VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION, COMPRISING VECTORFebruary 2023March 2026Allow3620NoNo
18042637COVID-19 VACCINES WITH TOCOPHEROL-CONTAINING SQUALENE EMULSION ADJUVANTSFebruary 2023March 2026Abandon3710NoNo
18020797FUSION PROTEINS COMPRISING SARS-COV-2 NUCLEOCAPSID DOMAINSFebruary 2023September 2025Allow3100NoNo
18005291RECOMBINANT POXVIRIDAE VECTOR EXPRESSING CO-STIMULATORY MOLECULESJanuary 2023January 2026Allow3610NoNo
18013863PERSISTENT MEMORY T-CELL RESPONSES TO CANCER AND INFECTIOUS-DISEASE ANTIGENS BY MANIPULATION OF AMINO ACID-CATABOLISM PATHWAYSDecember 2022November 2025Allow3510NoNo
18011064VACCINES, VACCINE PRIMING, AND ANTIGEN DOSE SPARINGDecember 2022March 2026Allow3910NoNo
18010418SWINE INFLUENZA A VIRUS VACCINE COMPRISING A NUCLEIC ACID CONSTRUCT HAVING A SPECIFIC ORDER OF GENESDecember 2022January 2026Allow3710NoNo
18010294MEASLES VIRUS VACCINE EXPRESSING SARS-COV-2 PROTEIN(S)December 2022February 2026Allow3810NoNo
18001576ORAL RECOMBINANT YEAST FOR EXPRESSING S PROTEIN OF NOVEL CORONAVIRUS, PREPARATION THEREFOR, AND APPLICATION THEREOFDecember 2022January 2026Abandon3710NoNo
18009684HIV VACCINE COMPOSITIONS, METHODS, AND USES THEREOFDecember 2022July 2025Allow3200NoNo
17998467SPIKE-IN REFERENCE STANDARD FOR USE IN DETECTING SAMPLE TARGET FROM DNA OR RNA ORGANISMNovember 2022February 2026Allow4010NoNo
17923283COMPOSITIONS, DEVICES AND METHODS FOR INDUCING IMMUNE RESPONSES TO INFECTIOUS AGENTSNovember 2022November 2025Allow3610NoNo
17997703ANTIGEN COMPOSITION FOR PREVENTING OR TREATING VIRAL INFECTIOUS DISEASESNovember 2022November 2025Allow3610NoNo
18048960MODIFIED IMMUNOGENIC PROTEINSOctober 2022October 2025Allow3610NoNo
17918304PARTICLES, DNA & RNAOctober 2022September 2025Allow3500NoNo
17937751INFECTIOUS DISEASE ANTIGENS AND VACCINESOctober 2022December 2025Allow3910NoNo
17914174CORONAVIRUS VACCINESeptember 2022February 2026Allow4110NoNo
17819204NUCLEIC ACID NANOSTRUCTURE PLATFORM FOR PROGRAMMING IMMUNE STIMULATIONAugust 2022January 2026Allow4220NoNo
17771349COMPOSITIONS COMPRISING V2 OPT HIV ENVELOPESApril 2022July 2025Allow3800NoNo
17753506INFLUENZA VIRUS VACCINES AND USES THEREOFMarch 2022July 2025Allow4000NoNo
17638005CROSS-REACTIVE EPITOPE FOR MULTIPLE SCLEROSISFebruary 2022July 2025Allow4110NoNo
17627861METHOD FOR PRODUCING A MODIFIED BACTERIOPHAGE WITHOUT GENOME MODIFICATIONJanuary 2022February 2026Allow4910NoNo
17626879SECOND GENERATION SENECA VALLEY VIRUS ONCOLYTIC THERAPY: COMPOSITIONS AND METHODS THEREOFJanuary 2022October 2025Allow4510NoNo
17624755VIRAL VECTOR THERAPYJanuary 2022February 2026Allow4910NoNo
17617831RNA CONSTRUCTDecember 2021October 2025Allow4710NoNo
17545818MOLECULAR DETECTION OF NOVEL CORONAVIRUSESDecember 2021December 2025Allow4910NoNo
17522150VIRUS-LIKE PARTICLESNovember 2021November 2025Allow4911YesNo
17441524EXTRACELLULAR VESICLES FOR VACCINE DELIVERYSeptember 2021July 2025Allow4611NoNo
17433416NOVEL FISH TOTIVIRUSAugust 2021June 2025Allow4600NoNo
17369405CANCER IMMUNOTHERAPY USING VIRUS PARTICLES AND IMMUNE CHECKPOINT THERAPYJuly 2021July 2025Allow4810NoNo
17299062RECOMBINANT HIV ENV POLYPEPTIDES AND THEIR USESJune 2021March 2026Allow5710NoNo
16579025BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINESeptember 2019January 2020Allow400NoNo
16388266COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITIONApril 2019July 2019Allow300NoNo
16385438BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINEApril 2019June 2019Allow200NoNo
16098303THERAPEUTIC HPV VACCINE COMBINATIONSNovember 2018August 2019Allow900NoNo
16174253VACCINES AND METHODS FOR CREATING A VACCINE FOR INDUCING IMMUNITY TO ALL DENGUE VIRUS SEROTYPESOctober 2018February 2020Allow1511NoNo
16074501METHODS OF PRODUCING VIRUSESAugust 2018July 2019Allow1201NoNo
16068845P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV)July 2018September 2019Allow1410NoNo
16063040COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDESJune 2018December 2019Allow1811NoNo
15777441DRIED INFLUENZA VACCINE PREPARATION AND METHOD FOR PRODUCING DRIED INFLUENZA VACCINE PREPARATIONMay 2018May 2020Allow2421NoNo
15777396VACCINE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION AND METHOD FOR MANUFACTURING VACCINE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATIONMay 2018June 2020Allow2521NoNo
15701352HEPATITIS B THERAPEUTIC VACCINESSeptember 2017July 2018Allow1001NoNo
15671360Anti-Viral Azide Containing CompoundsAugust 2017September 2018Allow1311NoNo
15548919HUMAN NEUTRALIZING ANTIBODIES BINDING TO INFLUENZA NEURAMINIDASEAugust 2017August 2018Allow1311YesNo
15494017Compositions and Methods for Increasing Immunogenicity of Glycoprotein VaccinesApril 2017September 2018Allow1711NoNo
15507525BISPHOSPHONATE-CONTAINING VACCINE PHARMACEUTICAL COMPOSITION FOR HUMORAL IMMUNITYFebruary 2017July 2019Allow2821YesNo
15501271COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITIONFebruary 2017December 2018Allow2311NoNo
15304019GENERALIZABLE ASSAY FOR VIRUS CAPSID ASSEMBLYOctober 2016September 2018Allow2321NoNo
15272650POROUS MEMBRANE-BINDING PEPTIDESSeptember 2016June 2017Allow901YesNo
15114298METHOD FOR THE VACCINATION AGAINST HIVJuly 2016July 2018Allow2411YesNo
15031329A NOVEL METHOD FOR THE PRODUCTION OF STABILE VACCINESApril 2016October 2019Allow4221NoNo
15022049METHOD FOR PRODUCING ENVELOPED VIRUSESMarch 2016July 2018Allow2821NoNo
14829158ALKYLATED INFLUENZA VACCINESAugust 2015July 2018Allow3531YesNo
14765365CELL LINES FOR VIRUS PRODUCTION AND METHODS OF USEAugust 2015December 2017Allow2831YesNo
14651635HIV THERAPEUTICS AND METHODS OF MAKING AND USING SAMEJune 2015May 2017Allow2411NoNo
14420720PRIMER SET FOR DETECTING BOVINE LEUKEMIA VIRUS AND USE THEREOFFebruary 2015September 2017Allow3131YesNo
14555288SELECTIVE BINDING OF BIOLOGICAL TARGETS TO SOLID PHASE UREIDESNovember 2014December 2016Allow2531YesNo
14382769USE OF CENTRIFUGATION-AIDED INFECTION TO INCREASE VIRUS TITERSeptember 2014June 2018Allow4551NoNo
14166965VACCINE COMPOSITIONJanuary 2014May 2018Allow5241NoNo
14152448COMPOSITIONS AND METHODS TO IMMUNIZE AGAINST HEPATITIS C VIRUSJanuary 2014September 2017Allow4441NoNo
14152782VACCINES FOR PROTECTION FROM AND TREATMENT OF ALZHEIMER'S DISEASEJanuary 2014May 2016Allow2811YesNo
14131061REAGENT STORAGE ON A DROPLET ACTUATORJanuary 2014November 2016Allow3521YesNo
14106461METHOD OF INDUCING THE PRODUCTION OF PROTECTIVE ANTI-HIV-1 ANTIBODIESDecember 2013June 2019Allow6051NoNo
13399654MODIFICATION OF RECOMBINANT ADENOVIRUS WITH IMMUNOGENIC PLASMODIUM CIRCUMSPOROZOITE PROTEIN EPITOPESFebruary 2012September 2016Allow5541NoNo
13345334Viral DiagnosticsJanuary 2012July 2014Allow3021YesNo
13142090Novel Porcine Circovirus Type 2B Isolate and Uses ThereofNovember 2011December 2013Allow3021NoNo
13272828CHIMERIC THERAPEUTICS, COMPOSITIONS, AND METHODS FOR USING SAMEOctober 2011December 2014Allow3821YesNo
13079472Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicityApril 2011October 2015Abandon5461YesNo
12736079RECOMBINANT VACCINIA VIRUS HAVING HEPATITIS C VIRUS GENEFebruary 2011April 2014Allow4341YesNo
12988341TAT DNA SEQUENCES, GENE CONSTRUCTS, VACCINE AND PROCESSES THEREOFJanuary 2011June 2016Allow6051YesNo
12995889NOVEL ANTIVIRAL PEPTIDE AGAINST AVIAN INFLUENZA VIRUS H9N2December 2010August 2014Allow4421YesNo
12795211CELL LINE STABLY EXPRESSING MUTATED ONCOPROTEIN E6 AND METHOD OF SCREENING ANTICANCER COMPOUND OF UTERINE CERVICAL CANCER USING THE SAMEJune 2010May 2014Allow4721YesYes
12600460SIGNALING PEPTIDESNovember 2009December 2012Allow3711YesNo
12595358NOVEL HIV-1 REVERSE TRANSCRIPTASE CODON DELETION AND ITS USE IN THE MANAGEMENT AND TREATMENT OF HIV INFECTIONSOctober 2009April 2016Allow6051YesYes
12246803FLU VIRUS HEMAGGLUTININ SPECIFIC MONOCLONAL ANTIBODIESOctober 2008December 2014Allow6041YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHESTNUT, BARRY A.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
1
(50.0%)
Not Allowed After Appeal Filing
1
(50.0%)
Filing Benefit Percentile
77.3%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner CHESTNUT, BARRY A - Prosecution Strategy Guide

Executive Summary

Examiner CHESTNUT, BARRY A works in Art Unit 1672 and has examined 51 patent applications in our dataset. With an allowance rate of 98.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner CHESTNUT, BARRY A's allowance rate of 98.0% places them in the 90% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CHESTNUT, BARRY A receive 1.94 office actions before reaching final disposition. This places the examiner in the 48% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHESTNUT, BARRY A is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a -4.8% benefit to allowance rate for applications examined by CHESTNUT, BARRY A. This interview benefit is in the 5% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 73.3% of cases where such amendments are filed. This entry rate is in the 93% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 142.9% are granted (fully or in part). This grant rate is in the 97% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.9% of allowed cases (in the 83% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.0% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.